Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, sonidegib (Odomzo®) cannot be endorsed for use within NHS Wales for the treatment of adult patients with locally advanced basal cell carcinoma who are not amenable to curative surgery or radiation therapy. |
||
|
||
Medicine details |
||
| Medicine name | sonidegib (Odomzo®) | |
| Formulation | 200 mg hard capsule | |
| Reference number | 2617 | |
| Indication | For the treatment of adult patients with locally advanced basal cell carcinoma who are not amenable to curative surgery or radiation therapy. |
|
| Company | Novartis Pharmaceuticals UK Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 09/12/2015 | |
| Date of issue | 10/12/2015 | |